[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619978":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":18,"locations":25,"responsibleParty":44,"collaborators":18,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":18,"enrollmentInfo":58,"targetDuration":18,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":74,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Shenyang Northern Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dapagliflozin group","EXPERIMENTAL","Participants receive dapagliflozin 10 mg orally once daily in addition to guideline-directed medical therapy for 6 months.",[13],"Drug: Dapagliflozin",{"label":15,"type":16,"description":17,"interventionNames":18},"Non-dapagliflozin group","NO_INTERVENTION","Participants receive guideline-directed medical therapy alone without any SGLT2 inhibitor for 6 months.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Dapagliflozin","10 mg\u002Fd for 6 months",[9],[26],{"facility":27,"status":18,"city":28,"state":29,"zip":18,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"General Hospital of Northern Theater Command","Shenyang","Liaoning","China","CN",{"type":33,"coordinates":34},"Point",[35,36],123.43278,41.79222,{"lat":36,"lon":35},[39],{"name":40,"role":41,"phone":42,"phoneExt":18,"email":43},"Yaling Han, MD","CONTACT","+86-24-23922184","cardiology@163.com",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Han Yaling","Prof.","100619978","phase-4-ccta-evaluation-of-sglt2i-related-pericoronary-fat-changes-in-non-diabetic-acs-patients-without-hf-100619978",false,"NCT07351643","CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF","Assessment of the Effects of SGLT2 Inhibitors on Pericoronary Fat in Non-diabetic ACS Patients Without Heart Failure Using CCTA","DAPA-PCAT","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Diagnosis of acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina)\n3. Undergoing percutaneous coronary intervention (PCI)\n4. Presence of multivessel coronary artery disease with at least one non-culprit vessel not undergoing revascularization (for CCTA follow-up assessment)\n5. Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Prior or current diagnosis of diabetes mellitus\n2. Prior or current diagnosis of chronic heart failure\n3. Treatment with any SGLT2 inhibitor within 4 weeks prior to enrollment\n4. Severe hepatic impairment\n5. History of recurrent urogenital infections\n6. Known allergy or intolerance to SGLT2 inhibitors\n7. Pregnancy or breastfeeding\n8. Systolic blood pressure \\\u003C90 mmHg and\u002For diastolic blood pressure \\\u003C60 mmHg\n9. Severe chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n10. Current participation in another interventional clinical trial\n11. Any other condition that, in the opinion of the investigator, would make the participant unsuitable for enrollment","ALL","18 Years",{"count":59,"type":60},110,"ESTIMATED","INTERVENTIONAL",[63],"PHASE4","The goal of this clinical trial is to learn if dapagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), can reduce coronary artery inflammation in people with acute coronary syndrome (ACS) who do not have diabetes or heart failure.\n\nCoronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries.\n\nThe main questions it aims to answer are:\n\n* Does dapagliflozin lower coronary artery inflammation as measured by FAI?\n* Does dapagliflozin slow the progression of coronary plaques?\n\nResearchers will compare participants who take dapagliflozin 10 mg daily plus standard therapy to those who receive standard therapy alone for 6 months.\n\nParticipants will:\n\n* Undergo percutaneous coronary intervention (PCI) for ACS\n* Have a baseline CCTA scan at 1 month after PCI, at which point they will be randomly assigned to receive dapagliflozin or standard care alone\n* Have a follow-up CCTA scan at 6 months after randomization\n* Have blood tests at the time of PCI, at randomization, and at 6 months after randomization\n* Receive follow-up phone calls at 3 and 6 months after randomization",[66,67],"ACS (Acute Coronary Syndrome)","SGLT2 Inhibitors",[69,70,71,72,73],"Fat attenuation index","SGLT2 inhibitors","Pericoronary adipose tissue","Residual inflammatory risk","Coronary CT angiography","NOT_YET_RECRUITING","2026-01-12",{"date":77,"type":78},"2026-01-20","ACTUAL",{"date":80,"type":60},"2026-02-25",{"date":82,"type":60},"2026-12-30",{"name":5,"class":6},1]